Principal Investigator: G. Nabozny
Description: Boehringer Ingelheim (BI) is a global pharmaceutical company with research focused on the discovery of new drugs to treat unmet medical needs in the areas of respiratory disease, oncology, virology, central nervous system disorders, cardiometabolic disease and immunology and inflammation. BI’s site in Ridgefield CT USA has a dedicated group of research scientists studying immune and inflammatory diseases with a particular emphasis on rheumatoid arthritis, severe psoriasis and multiple sclerosis. This group is responsible for all aspects of the early drug discovery process from target identification through early pre-clinical development and has research efforts to identify both NCE and NBE based therapeutics.
Interests of centre leader: Autoimmune disease patho-physiology. Identification of novel antibody and small molecule drugs for autoimmune disease. Predictive animal models, in-vitro assays and clinical biomarkers.
Role: Direct BI’s research efforts in rheumatoid arthritis, in particular new target identification, early drug discovery activities through testing in disease related animal models, in licensing activities and external collaborations.
Contribution: Assay and analysis of gene microarray based studies. Animal models of autoimmune disease.
Expertise: Expertise in new target validation, drug discovery and in vivo pharmacology